Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 12:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Intrauterine Device Complications Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Suction Cervical Stabilizer Compared to Standard Tenaculum for Intrauterine Procedures

NCT06193590
View directory record Official record
Conditions
Intrauterine Device (IUD), Abnormal Uterine Bleeding
Interventions
Carevix, Tenaculum
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Jun 11, 2026, 12:22 AM EDT
Withdrawn Phase 2 Interventional

IUD and Norethindrone Acetate for Treatment of Endometriosis

NCT04948489
View directory record Official record
Conditions
Endometriosis
Interventions
norethindrone acetate (NETA), Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 24 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Jun 11, 2026, 12:22 AM EDT
Completed No phase listed Observational

Occurrence and Trend of Pregnancies Growing Outside the Womb (Ectopic Pregnancy) 2009-2018. A Study on a Defined Group of Persons

NCT03670784
View directory record Official record
Conditions
Pregnancy, Ectopic
Interventions
No intervention
Other
Lead sponsor
Bayer
Industry
Eligibility
15 Years to 44 Years · Female only
Enrollment
3,922,877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jun 11, 2026, 12:22 AM EDT
Completed No phase listed Observational

Postpartum Glucose Tolerance With Levonorgesterel IUD Use in Women With Recent Gestational Diabetes

NCT01022645
View directory record Official record
Conditions
Gestational Diabetes, Glucose Intolerance, Type 2 Diabetes, Intrauterine Contraception
Interventions
Mirena (Levonorgestrel IUD), Paragard (Copper IUD ) or Tubal Ligation
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Jun 11, 2026, 12:22 AM EDT
Completed Not applicable Interventional Results available

Bleeding Patterns and Complications After Postpartum IUD Placement: a Pilot Study

NCT01309919
View directory record Official record
Conditions
Postpartum Period
Interventions
IUD, Diary
Device · Other
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Jun 11, 2026, 12:22 AM EDT
Recruiting Phase 2 Interventional

A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

NCT07107334
View directory record Official record
Conditions
Endometrioid Endometrial Adenocarcinoma
Interventions
Glucagon-like peptide 1 receptor agonist
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 11, 2026, 12:22 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer

NCT00788671
View directory record Official record
Conditions
Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System, Quality-of-Life Assessment
Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
7
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jun 11, 2026, 12:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Does Skyla Insertion Timing Impact Bleeding?

NCT03074903
View directory record Official record
Conditions
Vaginal Bleeding
Interventions
Intrauterine system
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Morristown, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Jun 11, 2026, 12:22 AM EDT
Completed No phase listed Observational

Patient Factors Associated With Fragmentation of Copper Intrauterine Devices Requiring Hysteroscopic Removal

NCT07351084
View directory record Official record
Conditions
Intrauterine Device Complications, Contraceptive Device Failure, IUD Fragmentation, Retained Intrauterine Device, Female Contraception, Women's Health, Reproductive Health
Interventions
Hysteroscopy
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
45 participants
Timeline
2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jun 11, 2026, 12:22 AM EDT
Not yet recruiting Phase 2 Interventional

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

NCT07349641
View directory record Official record
Conditions
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
Interventions
Medical Device Usage and Evaluation, Tirzepatide
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 11, 2026, 12:22 AM EDT
Active, not recruiting Phase 2 Interventional

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

NCT02397083
View directory record Official record
Conditions
Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions
Everolimus, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System
Drug · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
18
States / cities
Greeley, Colorado • Loveland, Colorado • Honolulu, Hawaii + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 11, 2026, 12:22 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement

NCT05875571
View directory record Official record
Conditions
IUD, Healthy Female, Contraception, IUD Insertion Complication
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jun 11, 2026, 12:22 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Study of Local Anesthesia as a Method to Decrease IUD Insertion Related Pain

NCT01967017
View directory record Official record
Conditions
IUD Insertion Complication, Pain Control
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Jun 11, 2026, 12:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Study on Medical Records of Women Using an Intrauterine Device (IUD) to Analyze the Risks That the IUD Will be Expelled or Perforates the Womb in Relation to Breastfeeding, the Point in Time When the IUD Was Inserted After Childbirth and in Relation to Different Types of IUDs

NCT03754556
View directory record Official record
Conditions
Intrauterine Devices
Interventions
Intrauterine device
Device
Lead sponsor
Bayer
Industry
Eligibility
Up to 50 Years · Female only
Enrollment
326,658 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Oakland, California • Pasadena, California • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Jun 11, 2026, 12:22 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Randomized Controlled Trial of No Strings Intrauterine Device (IUD) Removal Techniques

NCT05702242
View directory record Official record
Conditions
IUD Threads Not Visible, IUD Removal Complication
Interventions
IUD removal with no visible strings, Alligator forceps, Manual Vacuum Aspirator
Procedure · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jun 11, 2026, 12:22 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

UTERINE EVALUATION FOR THE IDENTIFICATION OF PATHOLOGY. This Study Will Compare the Intrauterine Pathology Detection Rate Between Standard of Care Hydrosonography, and a New Visual Saline Infusion Device Providing Direct Visualization of the Uterus.

NCT06394752
View directory record Official record
Conditions
Hysteroscopy, Hysteroscopy Technique, Fertility Issues, Uterus Abnormal, Gynecology, Visualization, Infertility Female
Interventions
Visual Saline Infusion, Hydrosonography
Device
Lead sponsor
Center for Reproductive Health & Gynecology
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Jun 11, 2026, 12:22 AM EDT
Completed Phase 2 Interventional Results available

Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients

NCT02035787
View directory record Official record
Conditions
Complex Atypical Hyperplasia, Endometrial Cancer
Interventions
Metformin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Jun 11, 2026, 12:22 AM EDT
Completed Not applicable Interventional Results available

Tracking IUD Bleeding Experiences: An Evaluation of Bleeding Profiles in New Intrauterine Device Users

NCT02311478
View directory record Official record
Conditions
Intrauterine Devices, Copper, Metrorrhagia, Menstruation, Menstrual Cycle
Interventions
T380A Intrauterine Copper Contraceptive
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Jun 11, 2026, 12:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)

NCT02824224
View directory record Official record
Conditions
Menorrhagia, Metrorrhagia, Medicated Intrauterine Devices
Interventions
Tamoxifen, Placebo (for Tamoxifen)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Jun 11, 2026, 12:22 AM EDT